US Edition
Breakthrough Alzheimer's drugs too pricey for NHS
- On June 19, 2025, NICE refused to recommend Alzheimer’s drugs donanemab and lecanemab for NHS use due to cost and modest benefits.
- The decision follows a 2024 review that found the drugs offer only small clinical benefits and lack long-term effectiveness evidence.
- NHS England estimated annual costs between £500 million and £1 billion, and experts warned treatments could displace other essential services.
- Chris Stokes of Lilly stated that if the healthcare system fails to provide pioneering scientific treatments to NHS patients, it is failing. Meanwhile, charities described the ruling as a difficult and disappointing blow.
- Lilly and Eisai plan to appeal the ruling, but people with early Alzheimer’s will likely face prolonged delays accessing these treatments on the NHS.
20 Articles
20 Articles
Central Maine News
Portland Press HeraldSen. Collins must take a stand on Alzheimer’s funding
My wife has Alzheimer’s. I’m 70 and she is 78 and I am her 24/7 caregiver. I get a break when she goes to a high-quality day program three days a week ($1,700 a month out of pocket). My wife is the best thing that ever happened to me and I love her. I’m not […]
Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost
Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said. The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information sub…
Coverage Details
Bias Distribution
- 80% of the sources are Center
To view factuality data please Upgrade to Premium
